Friday, July 10, 2026

Drug profile · INN

panobinostat

panobinostat (FARYDAK) is a histone deacetylase inhibitor.

EMA: approved Antineoplastic and immunomodulating agents (L01) L01XH03
Patents linked 0
Pipeline programs 7
News articles 0
Drug details — panobinostat
Class
Antineoplastic and immunomodulating agents (L01)
Route
Patents
0
Programs
7
Data quality
0.83

Quick answer

panobinostat (FARYDAK) is a histone deacetylase inhibitor.

Key facts

INN panobinostat
Brand FARYDAK
Mechanism Histone deacetylase inhibitor
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01XH03

Mechanism of action

Histone deacetylase inhibitor

Approval history

Authority Status Date
EMA approved

Pipeline programs

  1. Panobinostat Phase 3 · Novartis India · Multiple Myeloma
  2. 1.6 Phase 2 · Disc Medicine · HIV-1
  3. Panobinostat Phase 2 · Novartis India · Classical Hodgkin's Lymphoma
  4. Panobinostat Phase 2 · Zealand Pharma · Rhabdoid Tumor
  5. Panobinostat Capsules Phase 2 · pharma& · Multiple Myeloma
  6. SKSD00702 Phase 1 · BRIGHT MINDS BIOSCIENCES · Advanced Solid Tumors
  7. CINC424A2X01B Approved · Novartis India · This study is designed to accept patients with varied diseas

Related & competitor drugs

  1. abiraterone acetate Antineoplastic and immunomodulating agents (L02)
  2. anagrelide Antineoplastic and immunomodulating agents (L01)
  3. apremilast Antineoplastic and immunomodulating agents (L04)
  4. arsenic trioxide Antineoplastic and immunomodulating agents (L01)
  5. axitinib Antineoplastic and immunomodulating agents (L01)
  6. azacitidine Antineoplastic and immunomodulating agents (L01)

Frequently asked questions

What is panobinostat?

panobinostat (FARYDAK) is a histone deacetylase inhibitor.

What is the brand name for panobinostat?

FARYDAK is a marketed brand name for panobinostat. Check FDA Drugs@FDA for the current US label holder and prescribing information.